Bringing Toxicity Prediction to Chemists’ Desktops
Optibrium and Lhasa entered into a technology collaboration agreement that will integrate Lhasa’s Derek Nexus™ platform for knowledge-based prediction of compound toxicity as an optional plug-in module for Optibrium’s StarDrop software.
Are Current Cancer Drug Discovery Methods Flawed?
Vanderbilt researchers develop new approach to assess drug sensitivity in cells
Sigma Divisions Establish Screening Technology Deals
Sigma Life Science’s Sigma Advanced Genetic Engineering (SAGE) Labs, and Ekam Imaging are teaming up to develop a suite of preclinical services that will combine SAGE’s rat models of neurological disorders and Ekam’s functional magnetic resonance imaging (fMRI) technology.
![Funds will be used to continue clinical development of lead LAL deficiency enzyme replacement therapy.[© Bobby4237 - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesMarch2011March21_2011_Spreadof100dollarbills_SynagevaFinancing2005712466-324x160.jpg "Synageva Raises $25M Through Private Placement with Existing Investors")
Synageva Raises $25M Through Private Placement with Existing Investors
Funds will be used to continue clinical development of lead LAL deficiency enzyme replacement therapy.
FDA Clears Qiagen’s Rotor-Gene MDx RT-PCR IVD Platform and Influenza Assay
Firm will seek approval of a range of diagnostic assays for the platform.
Pfizer to Pony Up $68B for Wyeth
Question remains as to whether the transaction will help Pfizer’s failing revenues.
Amid reports of lower than anticipated fourth quarter earnings and major layoffs, Pfizer...
CMC Biologics to Manufacture ProtAffin’s Preclinical-Stage IL-8 Decoy
Glycan-binding anti-inflammatory protein designed to block activation of neutrophils.
Aduro BioTech Wins $250K in SBIR Grants and Contract with UNM...
Listeria-based platform will be leveraged against tularemia, HBV, and melanoma.
Rib-X Raises $20M to Progress Clinical-Stage Antibiotic Pipeline
Firm aims to push on with Phase IIb trial of quinolone candidate delafloxacin.
Tesaro Nabs AnaptysBio’s Immuno-Oncology Drug Candidates
Tesaro picked up the rights to antibody drug candidates from AnaptysBio targeting TIM-3, LAG-3 and PD-1 and dual-reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3.
